44th week of 2009 patent applcation highlights part 47 |
Patent application number | Title | Published |
20090270439 | Prophylactic/therapeutic agent for alzheimer's disease - A medicament effective for inhibiting onset of Alzheimer disease via intracellular aggregation mechanism is provided. A medicament for prophylaxis and treatment of Alzheimer disease comprising as an active ingredient apomorphine hydrochloride wherein cell death dependent upon intracellularly accumulated amyloid β proteins and/or p53 is inhibited; and/or wherein a level of intracellularly accumulated amyloid β proteins and/or phosphorylated tau proteins is lowered to improve energy production, protein metabolism and synaptic function of neurons so as to ameliorate the recognition capacity such as defects of memory. A medicament for prophylaxis and treatment of Alzheimer disease according to the present invention may allow for eradicative treatment of Alzheimer disease due to its inhibition of intracellular coagulation and accumulation of amyloid β proteins and intracellular activation of proteasome, and even prior to occurrence of massive neuronal death, may improve the function per se of neurons by reducing intracellularly accumulated amyloid β proteins to thereby contribute amelioration of the recognition function of Alzheimer disease patients. | 2009-10-29 |
20090270440 | BIOAVAILABILITY OF ACTIVE SUBSTANCES HAVING AN AMIDINE FUNCTION IN MEDICAMENTS - The invention relates to the use of N,N′-dihydroxyamidine (I), N,N′-dihydroxyamidine ether (II), N,N′-dihydroxyamidine diether (III), N,N′-dihydroxyamidine ester (IV), N,N′-dihydroxyamidine diester (V) or 4-hydroxy-1,2,4-oxadiazoline (VI) of the formulae cited above, wherein R represents hydrogen, an alkyl and/or aryl radical, as a substitute for an amidine function of a medicament for improving the bioavailability of the medicament. | 2009-10-29 |
20090270441 | MACROLIDES - The invention relates to the stabilization of poly-ene macrolides and to a particular macrolide obtained in crystalline form. | 2009-10-29 |
20090270442 | POLYMORPHS OF HYDROCHLORIDE SALT OF 5-(3-(ETHYLSULFONYL)PHENYL)-3,8-DIMETHYL-N-(1-METHYLPIPERIDIN-4-YL)-9H-PY- RIDO[2,3-B]INDOLE-7-CARBOXAMIDE AND METHODS OF USE THEREFOR - Polymorphic forms of the hydrochloride salt of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide (referred to herein as Compound 1) which has the formula: | 2009-10-29 |
20090270443 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS - Imidazo-containing compounds (e.g., imidazonaphthyridines, imidazopyridines) with an amino substituent at the 1-position, pharmaceutical compositions containing the compounds and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 2009-10-29 |
20090270444 | 1,7-Naphthyridines - There are provided according to the invention novel compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, | 2009-10-29 |
20090270445 | Thiazole compounds and methods of use - The invention relates to methods of using thiazole compounds of Formula I and Formula II and compositions thereof for treating diseases mediated by protein kinase B (PKB) such as cancer and other proliferative disorders where the variables have the definitions provided herein. | 2009-10-29 |
20090270446 | DIAMINE DERIVATIVES - The present invention relates to diamine compounds which inhibit activated blood coagulation factor X and exhibit an anticoagulant effect and there uses for treating various diseases based on thromboembolism. | 2009-10-29 |
20090270447 | 2-Aryl-and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof - The present invention discloses fused heterobicyclic 2-aryl- and 2-heteroarylthiazolyl compounds and their pharmaceutically acceptable salts and esters thereof, which are useful for inhibiting the growth of cancerous cells, inhibiting human breast carcinoma tumor growth in particular and to treat diseases or disorders associated with securin. | 2009-10-29 |
20090270448 | PHARMACEUTICAL FORMULATIONS COMPRISING CLOPIDOGREL - Melt granulate in the form of a solid state dispersion of the drug in a pharmaceutically acceptable carrier, wherein said melt granulate comprises a pharmaceutically active compound, preferably clopidogrel, at least one carrier material, and optionally pharmaceutically acceptable excipients and method of making said melt granulate. | 2009-10-29 |
20090270449 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS - Disclosed herein is a novel class of aminophenyl compounds having the structure: | 2009-10-29 |
20090270450 | CHEMICAL COMPOUNDS - The invention relates to chemical compounds of formula (I): | 2009-10-29 |
20090270451 | Piperdine Glycine Transporter Inhibitors - The present invention is directed to piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved. | 2009-10-29 |
20090270452 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS - Disclosed herein are compounds, compositions, and methods for enhancing smooth muscle function in a subject by administration of soluble epoxide hydrolase inhibitors and for treating subjects with smooth muscle disorders including erectile dysfunction, overactive bladder, uterine contractions and irritable bowel syndrome. | 2009-10-29 |
20090270453 | ANTI-MANIC EFFECTIVE DOSES OF SERTINDOLE - The present invention relates to uses of an anti-manic effective dose sertindole in the preparation of a pharmaceutical composition for the treatment of mania, and to methods of treating mania comprising administering said effective dose of sertindole. In separate aspects of the invention, said uses and methods are directed to treating manic episodes. | 2009-10-29 |
20090270454 | Sulfonamide containing compounds for treatment of inflammatory disorders - Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: | 2009-10-29 |
20090270455 | Therapeutic agent for intestinal diseases and visceral pain - The present invention relates to a therapeutic agent for irritable bowel syndrome of diarrhea type, ulcerative colitis, visceral pain or abdominal pain, which contains a compound of the following formula and which has 5-HT7 receptor antagonistic effect or an analogue thereof; and this therapeutic agent has an excellent therapeutic effect and a high safety: | 2009-10-29 |
20090270456 | Novel chemical compounds - This invention relates to newly identified compounds for inhibiting hYAK3 and/or CK2 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 and/or CK2 proteins. | 2009-10-29 |
20090270457 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2009-10-29 |
20090270458 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS - N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain. | 2009-10-29 |
20090270459 | Flea control agent containing N-Substituted indole derivative - Conventional control agents against fleas parasitic on animals do not have sufficient selective toxicity and are hence not safe for the animals to which the control agents are applied. The control agents are not always satisfactory also in control effect and quick-acting properties. Intensive studies were made on the insecticidal activity of N-substituted indole compounds against fleas and on the safety thereof for mammals including pets. As a result, it was found that an N-substituted indole derivative, e.g., 1-(3-chloro-5-trifluoromethylpyridin 2-yl)-3-(dichlorofluoromethylthio)indole, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-(dichlorofluoromethylthio)-indole, or 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-(trifluoromethylthio)indole, has high insecticidal activity and quick-acting properties and is lowly toxic to mammals including pets. | 2009-10-29 |
20090270460 | FXR AGONISTS - Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases. | 2009-10-29 |
20090270461 | Fungicide n-cycloalkyl-carboxamide, thiocarboxamide and n-substituted-carboximidamide derivatives - The present invention relates to N-cycloalkyl-carboxamide, N-cycloalkyl-thiocarboxamide and N-cycloalkyl-N-substituted carboximidamide derivatives of formula (I) wherein A represents carbo-linked, 5-membered heterocyclyl groups, T represents O, S, NR | 2009-10-29 |
20090270462 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS - The invention relates to 2-thio-substituted imidazole derivatives of the Formula I, and to methods of use thereof. | 2009-10-29 |
20090270463 | AMIDO DERIVATIVES-CONTAINED PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition containing a solid dispersion comprising an amide derivative or a salt thereof and a water-soluble polymer, wherein the pharmaceutical composition is not prepared by a melting method. The pharmaceutical composition contains the solid dispersion having an improved oral absorption, properties suitable for formulation, and an excellent stability. | 2009-10-29 |
20090270464 | Benzimidazole derivative and use as a II receptor antagonist - The present invention relates to a compound represented by the formula (I) | 2009-10-29 |
20090270465 | USE OF EPOTHILONE D IN TREATING TAU-ASSOCIATED DISEASES INCLUDING ALZHEIMER'S DISEASE - Methods of treating Tau-associated diseases, preferably tauopathies, are described using epothilone D that exhibit good brain penetration, long half-life, and high selective retention in brain, and provides effective therapies in treating tauopathies including Alzheimer's disease. | 2009-10-29 |
20090270466 | Epothilones C, D, E, and F, Preparation and Compositions - The present invention relates to epothilones C, D, E, and F, their preparation and their use for the production of therapeutic compositions and compositions for plant protection. | 2009-10-29 |
20090270467 | Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes - The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2009-10-29 |
20090270468 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity - This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases. | 2009-10-29 |
20090270469 | SUBSTITUTED OXAZOLIDINONES - The present invention relates to new oxazolidinone modulators of skeletal muscle function and tone, pharmaceutical compositions thereof, and methods of use thereof. | 2009-10-29 |
20090270470 | Compounds I - Compounds of formula I, | 2009-10-29 |
20090270471 | METHOD FOR INHIBITING MYCOTOXIN PRODUCTION - The present invention provides a method for prominently inhibiting the production in fungi of mycotoxin, which has serious effects on health of humans and other animals, and provides a mycotoxin production inhibitor. Mycotoxin content such as deoxinivalenol (DON) in harvested crops can be reduced without a correlation with the control effects against fungi by spraying a fungicide containing a benzimidazole-type fungicidal compound such as thiophanate-methyl as an active ingredient onto food crops such as wheat, barley, and the like. Concomitant use of the benzimidazole-type fungicidal compound and a sterol biosynthesis inhibitor (SBI agent) such as tebuconazole can further enhance the effect. | 2009-10-29 |
20090270472 | METHOD TO USE OXYMETAZOLINE TO INTERRUPT THE DEVELOPMENT OF THE COMMON COLD SYNDROME - This invention describes a new manner of treating the common cold. It claims that treatment with Oxymetazoline nasal spray at the time of onset of first cold symptom(s) can interrupt the development of the common cold syndrome and result in cure of the cold. | 2009-10-29 |
20090270473 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS - The invention relates to compounds having the formula: | 2009-10-29 |
20090270474 | Therapeutic Agent for Keratoconjunctival Disorder - An object of the present invention is to discover a new use of eprosartan or a salt thereof. Eprosartan or a salt thereof exhibits an excellent improving effect in a corneal disorder model, and therefore is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis and filamentary keratitis. | 2009-10-29 |
20090270475 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES - Disclosure is provided for imidazole-phenyl derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same. | 2009-10-29 |
20090270476 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF NEPHRITIS AND MANUFACTURING METHOD THEREOF - A pharmaceutical composition for treatment of nephritis of the present invention comprises a triprenylphenol compound as an active substance, preferably the triprenylphenol compound represented by the following general formula (1) as an active substance, and further preferably orniplabin represented as n=3 in the following general formula (1) as an active substance. | 2009-10-29 |
20090270477 | POLYMORPHS OF A HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONIST - This application is directed to a novel polymorph of a hydroisoindoline tachykinin receptor antagonist having the following structural formula A. | 2009-10-29 |
20090270478 | ION CHANNEL MODULATING ACTIVITY II - Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g., atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes. | 2009-10-29 |
20090270479 | Genetic and Epigenetic Alterations In the Diagnosis and Treatment of Cancer - Methylation of DNA in regions involved in transcriptional regulation can induce the binding of ICBP90 and the subsequent formation of multiprotein complexes which alter gene transcription. DNA methylation in tumor suppressor genes, or in other genes which are involved in mitigating tumorigenesis, can induce binding of ICBP90 to those genes. Bound ICBP90 can interact with a pRb2/p130 regulatory complexes to remodel chromatin and inhibit transcription of the gene. DNA methyltransferases, ICBP90, and the proteins comprising the pRb2/p130 complex are therefore therapeutic targets for the treatment of cancer. Abnormalities in these proteins can also be markers of cancerous or precancerous conditions. | 2009-10-29 |
20090270480 | Markers and Methods for Assessing and Treating Psoriasis and Related Disorders - A method for prognostic or diagnostic assessment of a skin-related disorder, such as psoriasis, in a subject correlates the presence, absence, and/or magnitude of a gene in a sample with a reference standard to determine the presence and/or severity of the disorder, and/or the response to treatment for the disorder. The method enables identification of the effectiveness of candidate therapies. | 2009-10-29 |
20090270481 | MODIFIED siRNA MOLECULES AND USES THEREOF - The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided. | 2009-10-29 |
20090270482 | ANALYSIS OF METHYLATED NUCLEIC ACID - The present invention provides a method for analysis methylation patterns in DNA and identifying aberrantly methylated genes in disease tissue. The invention also provides a method of identifying novel targets for therapeutic intervention and disease markers. Novel cancer targets are provided. | 2009-10-29 |
20090270483 | Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 2009-10-29 |
20090270484 | WWOX Vectors and Uses in Treatment of Cancer - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of cancer in a subject, by administering to the subject a polynucleotide encoding a functional WWOX gene product. | 2009-10-29 |
20090270485 | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site - Cell specific replication-competent viral vectors comprising a self processing peptide cleavage sequence are provided. The targeted replication-competent viral vectors include two or more co-transcribed genes under transcriptional control of the same heterologous transcriptional regulatory element (TRE), wherein at least a second gene is under translational control of a self processing cleavage sequence or 2A sequence. Exemplary vector constructs may further include an additional proteolytic cleavage site which provides a means to remove the self processing peptide sequence from the viral vector. | 2009-10-29 |
20090270486 | HUMAN RNASE III AND COMPOSITIONS AND USES THEREOF - The present invention provides polynucleotides encoding human RNase III and polypeptides encoded thereby. Methods of using said polynucleotides and polypeptides are also provided. | 2009-10-29 |
20090270487 | Compositions and methods for inhibiting the synthesis or expression of MMP-1 - The present invention relates to the specific inhibition of matrix metalloproteinase 1 (MMP-1) using agents which inhibit the synthesis or expression of MMP-1. Such agents are useful for suppressing invasion or metastasis of a tumor cell and in the treatment, prevention and management of cancer. | 2009-10-29 |
20090270488 | Process for the Selection of HIV-1 Subtype C Isolates, Selected HIV-1 Subtype Isolates, Their Genes and Modifications and Derivatives Thereof - Embodiments of the invention provide processes for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. A process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers 01032114, 00072724 and 00072725, respectively, by the European Collection of Cell Cultures) are also provided. | 2009-10-29 |
20090270489 | LONG-ACTING POLYPEPTIDES AND METHODS OF PRODUCING SAME - A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a peptide-of-interest are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed. | 2009-10-29 |
20090270490 | METHODS INVOLVING ALDOSE REDUCTASE INHIBITION - Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including inflammatory bowel disease, macular degeneration, or posterior capsule opacification. | 2009-10-29 |
20090270491 | MODULATION OF TUDOR-SN EXPRESSION - Compounds, compositions and methods are provided for modulating the expression of Tudor-SN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Tudor-SN. Methods of using these compounds for modulation of Tudor-SN expression and for diagnosis and treatment of diseases and conditions associated with expression of Tudor-SN are provided. | 2009-10-29 |
20090270492 | BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES - Biologically active compounds related to the bryostatin family of compounds, including methods of utilizing the same. | 2009-10-29 |
20090270493 | CYCLIC 1-(ACYLOXY)-ALKYL PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF - The present invention provides cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, methods of making cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs. The present invention also provides methods of using cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs. | 2009-10-29 |
20090270494 | Salts of Dihydroxyanthraquinone Carboxylic Acids and Their Therapeutic Use - A compound of general formula (I): wherein Xi is H or COR | 2009-10-29 |
20090270495 | Inhibitors of Phosphodiesterase Types 1 To 5 Based on Dioclein, Floranol, and Analogs Thereof - We disclose substances and a process of developing such substances as potent and selective inhibitors of isoforms of phosphodiesterases of types 1 to 5 (PDE1, PDE2, PDE3, PDE4, PDE5) based on two flavonoids: dioclein, floranol and natural or synthetic analogs thereof. They may be associated with cyclodextrins in inclusion complexes or using a biodegradable or non-biodegradable polymer, such as PLGA, PLA, PGA or mixtures thereof in controlled release devices. Their respective pharmaceutical compositions as well as pharmaceutical and pharmacologically acceptable excipients may be used for the study and treatment of cardiovascular diseases and associated products. | 2009-10-29 |
20090270496 | ANTIFUNGAL COMPOUNDS - Antifungal compounds having a benzofuran structure. Antifungals exhibit much less toxicity to human cells than amiodarone. These compounds are useful alone or in combination with other compounds having antifungal activity. Compounds of this invention exhibit synergistic antifungal activity in combination with antifungal amiodarone compounds. The invention provides pharmaceutical compositions useful for treating fungal infections, methods for treating fungal infections and compounds useful in such compositions for treating fungal infections. Compounds of this invention are further useful as antifungal agents for the prevention and or treatment of fungal infections in plants. The invention includes agriculturally useful compositions comprising one or more compounds of this invention which exhibit fungistatic or fungicidal function against one or more plant pathogen is a fungus. | 2009-10-29 |
20090270497 | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors - Described herein are compositions and methods for treating a subject suffering from a non-localized inflammatory condition (or any symptoms associated with such inflammation), including systemic inflammation, and inflammatory conditions affecting the large portions of or the whole body, or sepsis by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound that is a pan-HDAC inhibitor. Also described herein are methods for decreasing iNOS and cytokine expression by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound that is a pan-HDAC inhibitor. | 2009-10-29 |
20090270498 | Lipoxin Compounds and Their use in Treating Cell Proliferative Disorders - Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed. | 2009-10-29 |
20090270499 | Process for Synthesizing Atazanavir - This invention relates to a process for synthesizing Atazanvir, including novel intermediates and novel steps to various intermediates along the synthetic pathway. | 2009-10-29 |
20090270500 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS - This invention relates to novel 4-trimethylammoniobutyrates of the formula | 2009-10-29 |
20090270501 | COMPOSITION AND METHOD FOR INCREASING THE ANABOLIC STATE OF MUSCLE CELLS - A nutritional supplement comprising at least a therapeutically effective amount of ethyl pyruvate and a therapeutically effective amount of at least one α-hydroxy branched-chain amino acid metabolite is provided by the present invention. The ingredients of the present nutritional supplement substantially simultaneously act to induce a anabolically-favorable state for muscle by substantially simultaneously maintaining blood and muscle physiological pH levels as well as increasing cellular concentrations of branched-chain amino acids. Both a composition and a method are provided by the present disclosure. | 2009-10-29 |
20090270502 | Method for Lowering Risk of Cardiovascular Diseases - The present invention relates to a method for lowering risk of cardiovascular diseases in human, particularly for lowering low density lipoprotein cholesterol (LDL-C) concentration and oxidative stress level while maintaining sufficient high density lipoprotein cholesterol (HDL-C) concentration in human, and to a dietary formulation and a fat or fat blend suitable for human consumption for resulting in the same. The method is by way of controlling daily dietary fat and antioxidants consumption so that: daily dietary fat accounts for 20-40% of the total daily dietary energy intake; 10-20% wt of the fatty acids in daily dietary fat are saturated fatty acids (SFAs); 20-35% wt of the fatty acids in daily dietary fat are polyunsaturated fatty acids (PUFAs); 45-70% wt of the fatty acids in daily dietary fat are monounsaturated fatty acids (MUFAs); and the ratio of antioxidants to polyunsaturated fatty acids (PUFAs) in daily dietary fat is ranging from about 15-70 ppm antioxidants/% wt PUFAs. | 2009-10-29 |
20090270503 | NUTRITIONAL SUPPLEMENTS - The present disclosure relates to novel nutritional methods and compositions containing essential fatty acids which optimize embryonic, fetal and child neurological development and provides improved nutritional support for women prior to and during lactation. Further the methods and compositions improve gestational length and birth weight. The nutritional methods and compositions are also intended for use by women to optimize infant neurological development and provide improved nutritional support for women prior to, during and after lactation. | 2009-10-29 |
20090270504 | Treatment of Huntington's Disease With EPA - Analysis of the huntington gene provides a method for identifying patients likely to respond to treatment of Huntington's disease with eicosapentaenoic acid, EPA. | 2009-10-29 |
20090270505 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES - This invention relates to novel 4-dimethylaminobutyric acid derivatives of the formula | 2009-10-29 |
20090270506 | CRYSTALLINE STRUCTURE OF OXIDOSQUALENE SYNTHASE - The present invention relates to crystal forms of mammalian OSC and the crystal structure information obtained from them, to methods of preparing such crystal forms, and to their use for the identification and/or design of inhibitors of OSC activity. A further subject matter of the invention are methods for the identification and/or design of inhibitor compounds of OSC activity, the inhibitor compounds of OSC activity identified by these methods and their use in pharmaceutical compositions for the treatment and/or prevention of diseases which are associated with OSC comprising hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections and gallstones, and/or treatment and/or prophylaxis of impaired glucose tolerance, diabetes, tumors and/or hyperproliferative disorders, preferably for the treatment and/or prophylaxis of hypercholesterolemia and/or hyperlipemia. | 2009-10-29 |
20090270507 | Concentrated Liquid Thyroid Hormone Composition - This invention is directed generally to a liquid pharmaceutical composition comprising at least one thyroid hormone (particularly a composition further comprising at least one cyclodextrin compound), a process for making such a composition and a method of using such a composition to treat a condition associated with impaired thyroid hormone function. | 2009-10-29 |
20090270508 | GluR2 receptor modulators - The present invention provides for compositions and methods for modulating the GluR2 receptor. It is based, at least in part, on the discovery, by X-ray crystallography, that a known GluR2 agonist binds to the receptor in two different orientations, thereby diminishing its potency. The present invention provides for structural alternatives in which alternative binding possibilities are substantially eliminated. | 2009-10-29 |
20090270509 | NITRIC OXIDE-RELEASING MOLECULES - This invention relates to compositions comprising carbon-based diazeniumdiolates that release nitric oxide (NO). The carbon-based diazeniumdiolated molecules release NO spontaneously under physiological conditions without subsequent nitrosamine formation. The present invention also relates to methods of preparing the carbon-based diazeniumdiolated molecules, compositions comprising such molecules, methods of using such compositions, and devices employing such molecule compositions. | 2009-10-29 |
20090270510 | GLYCINE TRANSPORT INHIBITORS - The present invention relates to compounds of formula (I), or salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof. | 2009-10-29 |
20090270511 | PRODRUGS OF INHIBITORS OF CATHEPSIN S - The present invention provides compounds of formula (I) which are prodrugs of inhibitors of cathepsin S and as such are useful in the prevention and treatment of cathepsin S dependent diseases and conditions including, but not limited to, chronic obstructive pulmonary disease (COPD) and pain. | 2009-10-29 |
20090270512 | Pan-Antagonists For The Androgen Receptor And Androgen Receptor Mutants Associated With Anti-Androgen Withdrawal - Disclosed herein are novel antagonists of the androgen receptor and androgen receptor mutations associated with clinical failure of currently prescribed anti-androgens and use of said antagonists in the treatment of conditions associated with inappropriate activation of the androgen receptor. | 2009-10-29 |
20090270513 | 3,5-DIHYDROXY-2,4-CYCLOHEXADIENONES AND THEIR DERIVATIVES, DIETARY COMPOSITIONS AND FORTIFIED FOOD CONTAINING THEM AND THEIR USES - The present invention refers especially to 3,5-dihydroxy-2,4-cyclohexadienones of the general formula (I) wherein R | 2009-10-29 |
20090270514 | Methods for Regulating Gelation of Polysaccharide Solutions and Uses Thereof - The present invention provides a method for preparing chito san solutions to allow regulating the conditions in which the chitosan solution will gel. The present invention also provides methods for using chitosan solutions as compositions and for using chitosan solutions in vitro and in vivo. | 2009-10-29 |
20090270515 | ACTIVE INGREDIENT CONTAINING STABILISED SOLID MEDICINAL FORMS AND METHOD FOR THE PRODUCTION THEREOF - The invention relates to solid medicinal forms containing at least one active ingredient and at least one pharmaceutically compatible, water soluble drying agent which is selected from the group consisting of trimagnesium dicitrate and/or calcium chloride, the solid medicinal form having a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less. The invention also relates to solid medicinal forms containing a moisture-sensitive active ingredient and trimagnesium dicitrate. | 2009-10-29 |
20090270516 | Process for Producing Optically Active Theaspirane - A simplified production method of stereoisomer of theaspiran having high optical purity has been desired. An alcohol compound having a specific skeleton is enantioselectively esterified with an enzyme, or an ester compound having a specific skeleton is enantioselectively hydrolyzed with an enzyme. The resultant optically active ester or optically active alcohol is used. Thus, optically active theaspiran having a desired configuration and having a high optical purity is obtained in a satisfactory yield. | 2009-10-29 |
20090270517 | Emulsion With Tolerance to Alcohol and Process for Producing the Same - A monohydric-alcohol-containing emulsion that is more stable than prior art emulsions. | 2009-10-29 |
20090270518 | CATALYST WITH SUPPORT STRUCTURE - The present invention provides a catalyst carrier, catalyst and catalyst precursor comprising a refractory metal oxide and support structure comprising a wire gauze having between 100 | 2009-10-29 |
20090270519 | POROUS POLYMER STRUCTURES - A method of preparing a porous polymer structure comprising the steps of: forming a liquid composition comprising at least one polymer dissolved in at least one solvent; subjecting the liquid composition to stress, and if necessary also to a reduction in temperature, to cause the liquid composition to form a bi-continuous phase separated composition, the bi-continuous phase separated composition comprising a polymer rich phase and a polymer poor phase; solidifying the at least one polymer in the polymer rich phase; and removing the polymer poor phase from the polymer rich phase to provide the porous polymer structure having a bi-continuous morphology from the polymer rich phase. | 2009-10-29 |
20090270520 | PROCESS FOR PRODUCING FLEXIBLE POLYURETHANE FOAM - To produce a flexible polyurethane foam molded product having good air flow and cushioning characteristic and having cell roughening at the skin portion suppressed by using a raw material derived from a natural fat/oil. | 2009-10-29 |
20090270521 | METHOD FOR MANUFACTURING A FIRE RESISTANT FOAM - A method for the manufacture of a fire resistant foam, which includes mixing together the ingredients of a polyol, a di-isocyanate and a sodium silicate, wherein the sodium silicate is heated to liquefy it enough to facilitate mixing it with the polyol and the di-isocyanate. A fire resistant foam, which includes a foam manufactured in accordance with the above mentioned method. | 2009-10-29 |
20090270522 | BLOWING AGENTS FOR POLYMERIC FOAMS - Provided are foam blowing agents comprising one or more chlorofluoroolefins selected from 1,2-dichloro-1,2-difluoroethene, 3,3-dichloro-3-fluoropropene, 2-chloro-1,1,1,3,4,4,4-heptafluoro-2-butene, and 2-chloro-1,1,1,4,4,4-hexafluoro-2-butene, as well as foams produced therefrom. | 2009-10-29 |
20090270523 | Polyurethane foam-forming compositions containing polysilsesquioxane cell opening agents - The present invention relates to polyurethane foam-forming composition containing polysilsesquioxanes that provide high resilience flexible polyurethane molded foams having improved foam dimensional stability. | 2009-10-29 |
20090270524 | POLYLACTIC ACID FOAM - The invention relates to polylactic acid foam comprising a resin composition that comprises polylactic acid (A), polyolefin resin (B) and a polyolefin resin copolymer (C) wherein the weight ratio of the polylactic acid to the sum of the polyolefin resin and polyolefin resin copolymer in the resin composition, (A)/{(B)+(C)}, is in the range of 0.2-6. | 2009-10-29 |
20090270525 | THERMOPLASTIC ELASTOMER COMPOSITION, FOAM PRODUCT, AND PROCESS FOR PRODUCTION OF THE COMPOSITION OR FOAM PRODUCT - A thermoplastic elastomer composition having a melt tension of 5.0 cN or more at 210° C. and a pulling rate of 2.0 m/min and a compression set of 80% or less when measured according to JIS K6262 at 70° C. and 22 hours is provided. The composition is obtained by dynamically treating a mixture of (A) a rubber and (B) a thermoplastic resin (B-1) and/or a thermoplastic resin composition (B-2) with heat in the presence of (C) a crosslinking agent. | 2009-10-29 |
20090270526 | ENCAPSULANT COMPOSITION AND METHOD FOR FABRICATING ENCAPSULANT MATERIAL - An encapsulant composition is provided, including at least one resin monomer, a filler and a photoinitiator, wherein the at least one resin monomer is selected from the group consisting of acrylic resin monomer, epoxy resin monomer, silicone resin monomer and compositions thereof, and the filler is of about 0.1˜15 weight % of the encapsulant composition. A method for forming encapsulant materials is also provided. | 2009-10-29 |
20090270527 | CEMENT PRODUCTS AND METHODS OF MAKING AND USING THE SAME - Disclosed are cement products, methods of forming cement using the cement product, and methods of using the cement product in orthopedic and dental applications. Generally, the disclosed cement product includes a first component and a second component. The first component comprises a polymerizable resin comprising ethylenic unsaturated double bond, a suitable glycidyl group and/or a suitable isocyanate group. The second component includes a compound comprising more than one type of amine selected from the group consisting of primary amine, secondary amines, tertiary amines and quaternary amines. Alternatively, the second component includes a compound comprising a suitable mercapto (SH—) group, a hindered amine or a dimethylthiotoluenediamine (DMTDA). Optionally, the cement product includes a filler and/or a bioactive component to promote bone formation. | 2009-10-29 |
20090270528 | RESIN SYSTEMS FOR DENTAL RESTORATIVE MATERIALS - The disclosure provides a new photopolymerizable resin system for dental restorative materials. The resin system utilizes a thiol-ene component as the reactive diluent in dimethacrylate systems. The ternary resin system comprises a thiol monomer, an ene monomer and a dimethacrylate monomer. Use of an off-stoichiometric ratio of thiol:ene functional groups in favor of excess thiols results in enhanced overall functional group conversion, improved polymer mechanical properties, and reduced shrinkage stress of the ternary system when compared to either traditional dimethacrylate or thiol-ene resin systems. | 2009-10-29 |
20090270529 | (METH)ACRYLIC-MODIFIED SILOXANE COMPOUNDS - Provided is a siloxane compound having one end modified with at least one (meth)acrylic group via a spacer, the spacer being a straight chain having at least three ether bonds or a branched structure having at least one ether bond. The (meth)acrylic-modified siloxane compound is added to a heat or photo-curable composition, which cures into a product exhibiting water repellent, antifouling, lubricating and other properties inherent to siloxane. | 2009-10-29 |
20090270530 | Biodegradable resin composition and molded body and production method thereof - There is disclosed a biodegradable resin composition containing 100 parts by mass of a biodegradable polyester resin containing not less than 50% by mass of polylactic acid, 0.1 to 10 parts by mass of a layered silicate, 0.1 to 5 parts by mass of a carbodiimide compound and 0.01 to 5 parts by mass of a phosphite organic compound. Alternatively, the biodegradable resin composition contains a phosphite organic compound and at least one additive selected from the group consisting of a hindered phenol compound, a benzotriazole compound, a triazine compound and a hindered amine compound in an amount of 0.01 to 5 parts by mass in total, instead of containing 0.01 to 5 parts by mass of the phosphite organic compound. | 2009-10-29 |
20090270531 | LUBRICATING OIL ADDITIVE COMPOSITION AND METHOD OF MAKING THE SAME - A post-treated polymeric dispersant which comprises reacting (I) a post-treating agent selected from a cyclic carbonate, a linear mono-carbonate, a linear poly-carbonate, an aromatic polycarboxylic acid or an aromatic polycarboxylic anhydride or an aromatic polycarboxylic acid ester and (II) an oil-soluble lubricating oil additive composition prepared by the process which comprises reacting a copolymer, with at least one ether compound and with at least one aliphatic compound capable of reacting with at least one monocarboxylic acid or ester thereof, or dicarboxylic acid, anhydride or ester thereof. | 2009-10-29 |
20090270532 | Process for Production of Resin-Coated Heat Accumulator Particles - The present invention provides a method of producing resin-coated latent heat storage particles which can be continuously supplied to a producing step of a water-curable-type inorganic material (gypsum, cement, and the like), with a latent heat storage component in the particles hard to volatilize. | 2009-10-29 |
20090270533 | HEAT-CURABLE POWDER COATING COMPOSITION - Disclosed is a heat-curable powder coating composition that allows the formation of a coating film having outstanding long-term corrosion resistance, as well as outstanding chipping resistance, flexibility, and adhesion. | 2009-10-29 |
20090270534 | Processes and Manufacturing Methods to Produce an Aqueous Thermosetting Fire-Rated Fire-Retardant Polymeric Adhesive Composition for Manufacturing Interior or Exterior Fire-Rated Cellulosic Products - Disclosed is a fire-retardant non-corrosive composition, as well as a process for the production of porous materials, wherein the process is conducted in the presence of the said fire- retardant, non-corrosive composition. The fire-retardant, non-corrosive composition of the subject application includes a flame-retardant agent, preservative composition, casein liquid modified melamine resin adhesive, and a monomeric-polymeric MDI catalyst. The composition material and the product resulting from the process of the subject application have fire retardant, non-corrosive properties and protection from fungus and insects. | 2009-10-29 |
20090270535 | MIXTURES OF STERICALLY HINDERED AMINES FOR THE STABILISATION OF POLYMERS - This invention relates to mixtures of new polypiperidine compounds of general formula (I) with other known polypiperidine compounds which impart to polymer materials of different kinds, in particular polyolefins, high stability towards oxidative action and photodegradation. | 2009-10-29 |
20090270536 | OLIGOMERIC STERICALLY HINDERED AMINES AND THEIR USE AS POLYMER STABILISERS - This invention relates to new polypiperidine compounds of general formula (I) which give different kinds of polymer materials, in particular polyolefins, high stability towards oxidative action and photodegradation. | 2009-10-29 |
20090270537 | NON-AQUEOUS PIGMENTED INKJET INKS - A non-aqueous inkjet ink includes C.I. Pigment Yellow 150 and a polymeric dispersant according to Formula (I): | 2009-10-29 |
20090270538 | PARTICULATE WATER-ABSORBENT POLYMER AND PRODUCTION METHOD THEREOF - An object of the present invention is to provide a method for producing a particulate water-absorbent polymer particle having remarkably improved long-term color stability, without an adverse effect (such as a delay in polymerization) on synthesis of the particulate water-absorbent polymer. The method includes the steps of polymerizing a monomer aqueous solution (B) containing (i) at least one type of monomer (A) that is capable of forming a particulate water-absorbent polymer by polymerization, (ii) at least one type of crosslinking agent, (iii) at least one type of polymerization initiator and (iv) an organophosphorus compound in an amount of not less than 1 but not more than 100 ppm by mass with respect to the monomer (A) so as to form a hydrogel polymer, and drying the hydrogel polymer. The method enables to provide an excellent particulate water-absorbent polymer that realizes (i) long-term color stability and improvement in urine tolerance and (ii) absorbing property, which are in such a trade-off relationship. In this way, the above object is attained. | 2009-10-29 |